hepatitis

[Signal Transduction and Targeted Therapy] A novel ionizable lipidoid nanoparticle and a state-of-the-art lyophilization technology were developed, enabling to deliver small interfering RNA (siRNA) targeting apolipoprotein B into the hepatocytes with an ED50 of 0.05 mg/kg after intravenous injection.

[Cell Death & Disease] Investigators confirmed that ETV4 was significantly upregulated by Hepatitis B virus X protein (HBx) and involved in super-enhancer-associated chromatin accessibility. Increased expression of ETV4 promoted HCC cell invasion and metastasis by upregulating DVL2.

[eLife] Scientists used high-throughput sequencing of memory CD4 TCRβ repertoire and machine learning to showed that individuals with preexisting vaccine-reactive memory CD4 T cell clonotypes elicited earlier and higher antibody titers and mounted a more robust CD4 T cell response to hepatitis B vaccine.

[Journal of Hepatology] The authors reported that HCV infection was favored by heparanase-1 (HPSE), and upregulated HPSE expression and secretion, which may have resulted in potentially pathogenic alterations of the extracellular matrix.

[Signal Transduction and Targeted Therapy] Investigators performed whole-genome sequencing on 40 pairs of primary and early-recurrent hepatitis B virus (HBV)-related hepatocellular carcinoma tumors from patients who received curative resection, and from four patients whose primary and recurrent tumor were extensively sampled.

[Aligos Therapeutics, Inc.] Aligos Therapeutics, Inc. announced that the first chronic hepatitis B patient has been dosed in the multiple ascending dose portion of Study ALG-020572-401 which is evaluating antisense oligonucleotide ALG-020572.